Zolla-Pazner S, Burda S, Andrus L, Prince A; National Conference on Human Retroviruses and Related Infections.
Program Abstr First Natl Conf Hum Retrovir Relat Infect Natl Conf Hum Retrovir Relat Infect 1st 1993 Wash DC. 1993 Dec 12-16; 73.
NYU Medical Center, NY.
Preparations containing pooled human immunoglobulin derived from HIV-infected individuals (HIVIG) have been reported to possess the ability to neutralize HIV-1. Human monoclonal antibodies (humAbs) to HIV-1 derived from the cells of HIV-seropositive individuals also have neutralizing capability. We have attempted to enhance the neutralizing ability of HIVIG by combining it with humAbs targeted towards different epitopes on the HIV envelope. The humAbs used included: 694/98-D which recognizes the GRAF sequence of the gp120-V3 region, 447-52-D, specific for the GPGR sequence of the same region, and 729-D, which is directed against the CD4 binding domain of gp120. The assay used was the modified syncytium formation assay (Nara et al., Laal et al.) that measures the neutralization of cell-free virus. The results show that the addition of 0.2 to 1.3% of these humAbs to HIVIG (on a weight-to-weight basis) reduces by 2.5- to 5-fold the amount of HIVIG required to achieve 50% neutralization. The combinations tested demonstrated an additive rather than synergistic interaction (CI50=0.7-1.3). These results suggest that the amount of HIVIG required for passive immunization could be greatly decreased by the addition of small amounts of humAbs.
Publication Types:
Keywords:
- AIDS Vaccines
- Acquired Immunodeficiency Syndrome
- Animals
- Antibodies, Monoclonal
- Antigens, CD4
- Epitopes
- HIV Envelope Protein gp120
- HIV Infections
- HIV Seropositivity
- HIV hyperimmune globulin
- HIV-1
- Humans
- Immunization, Passive
- Immunoglobulins
- Immunoglobulins, Intravenous
- immunology
Other ID:
UI: 102214073
From Meeting Abstracts